Kairos Pharma, Ltd.
$1.85
$0.01 (+0.54%)
$1.76Day Range$1.89
Key Statistics
Market Cap
$6.23M
Shares Outstanding
3.4M
Primary Exchange
XASE
Currency
USD
Type
CS
IPO Date
Sep 16, 2024
Round Lot
100
Locale
US
Trading Data
Day Open
$1.79
Day High
$1.89
Day Low
$1.76
Volume
38.0K
VWAP
$1.81
Prev Close
$1.84
Transactions
--
Acc. Volume
--
About Kairos Pharma, Ltd.
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. The company is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The product portfolio of the company consists of Pre-clinical or clinical-trial stage drug candidates, Therapeutic agents, and other technologies for treating diseases.
PHARMACEUTICAL PREPARATIONSSIC 28341 employees2355 WESTWOOD BLVD. #139, LOS ANGELES, CA, 90064818-404-5541IPO Sep 16, 2024US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001962011
- Composite FIGI
- BBG01JLR1R85
- Share Class FIGI
- BBG01JLR1S38
- Ticker Root
- KAPA
- SIC Code
- 2834
About Kairos Pharma, Ltd. (KAPA) Stock
Kairos Pharma, Ltd. (KAPA) closed the 2026-09-15 session at $1.85, up 0.54% versus the previous close (+0.01). The stock opened at $1.79 and traded between $1.76 and $1.89 during that session. Session trading volume was 38K shares. The volume-weighted average price (VWAP) is $1.81.
Kairos Pharma Ltd is a clinical-stage biopharmaceutical company. The company is engaged in therapeutics for cancer patients that are designed to overcome key hurdles in immune suppression and drug resistance. These therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. The product portfolio of the company consists of Pre-clinical or clinical-trial stage drug candidates, Therapeutic agents, and other technologies for treating diseases.
Kairos Pharma, Ltd. has a market capitalization of $6.2 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. KAPA is listed on the XASE exchange. The company employs approximately 1 people. Kairos Pharma, Ltd. is headquartered in LOS ANGELES, CA. The recorded listing date is 2024-09-16.
On this page you can find market KAPA stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.